AgomAb Therapeutics

AgomAb Therapeutics is a biotechnology company developing novel therapeutic approaches designed to preserve and restore organ function in fibrotic diseases. With deep expertise in growth factor biology, we have pioneered and advanced innovative treatments aimed at addressing fibrosis, repairing tissue architecture, and restoring organ function. By combining cutting-edge R&D approaches with an ambitious corporate strategy, we are developing a broad pipeline of clinical assets targeting two key signaling pathways involved in fibrosis: Transforming Growth Factor β (TGFβ) and Hepatocyte Growth Factor (HGF).